Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression

被引:7
|
作者
Domowicz, Miriam S. [1 ]
Chan, Wen-Ching [2 ]
Claudio-Vazquez, Patricia [1 ]
Gonzalez, Tatiana [1 ]
Schwartz, Nancy B. [1 ,3 ]
机构
[1] Univ Chicago, Med Ctr, Dept Pediat, Biol Sci Div, 5841 S Maryland Ave,MC 5058, Chicago, IL 60637 USA
[2] Univ Chicago, Ctr Res Informat, Biol Sci Div, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Biochem & Mol Biol, Biol Sci Div, Chicago, IL 60637 USA
关键词
Neuronal ceroid lipofuscinoses; Transcriptome; Lysosomal tripeptidyl peptidase 1; Pediatric neurodegeneration; Neuroinflammation; Choroid plexus; NEURONAL CEROID-LIPOFUSCINOSIS; TRIPEPTIDYL-PEPTIDASE-I; MATRIX METALLOPROTEINASE-12; CEREBROSPINAL-FLUID; GENE; CELLS; NEUROINFLAMMATION; PATHOLOGY; EXPRESSION; PROTEINS;
D O I
10.1186/s12974-021-02302-z
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Neuronal ceroid lipofuscinoses, (NCLs or Batten disease) are a group of inherited, early onset, fatal neurodegenerative diseases associated with mutations in 13 genes. All forms of the disease are characterized by lysosomal accumulation of fluorescent storage material, as well as profound neurodegeneration, but the relationship of the various genes' function to a single biological process is not obvious. In this study, we used a well-characterized mouse model of classical late infantile NCL (cLINCL) in which the tripeptidyl peptidase 1 (Tpp1) gene is disrupted by gene targeting, resulting in loss of detectable TPP1 activity and leading to progressive neurological phenotypes including ataxia, increased motor deficiency, and early death. Methods In order to identify genes and pathways that may contribute to progression of the neurodegenerative process, we analyzed forebrain/midbrain and cerebellar transcriptional differences at 1, 2, 3 and 4 months of age in control and TPP1-deficient mice by global RNA-sequencing. Results Progressive neurodegenerative inflammatory responses involving microglia, astrocytes and endothelial cells were observed, accompanied by activation of leukocyte extravasation signals and upregulation of nitric oxide production and reactive oxygen species. Several astrocytic (i.e., Gfap, C4b, Osmr, Serpina3n) and microglial (i.e., Ctss, Itgb2, Itgax, Lyz2) genes were identified as strong markers for assessing disease progression as they showed increased levels of expression in vivo over time. Furthermore, transient increased expression of choroid plexus genes was observed at 2 months in the lateral and fourth ventricle, highlighting an early role for the choroid plexus and cerebrospinal fluid in the disease pathology. Based on these gene expression changes, we concluded that neuroinflammation starts, for the most part, after 2 months in the Tpp1(-/-) brain and that activation of microglia and astrocytes occur more rapidly in cerebellum than in the rest of the brain; confirming increased severity of inflammation in this region. Conclusions These findings have led to a better understanding of cLINCL pathological onset and progression, which may aid in development of future therapeutic treatments for this disease.
引用
收藏
页数:18
相关论文
共 50 条
  • [11] EXPERT OPINION ON THE MANAGEMENT OF CLN2 DISEASE
    Williams, Ruth E.
    Cohen-Pfeffer, Jessica
    Adams, Heather
    Blohm, Martin
    de los Reyes, Emily
    Denecke, Jonas
    Drago, Kristen
    Fairhurst, Charlie
    Frazier, Margie
    Guelbert, Norberto
    Kiss, Szilard
    Kofler, Annamaria
    Lawson, John
    Lehwald, Lenora
    Leung, Mary-Anne
    Mikhailova, Svetlana
    Mink, Jonathan
    Nickel, Miriam
    Shediac, Renee
    Sims, Katherine
    Specchio, Nicola
    Topcu, Meral
    von Lobbecke, Ina
    West, Andrea
    Schulz, Angela
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (03) : 293 - 293
  • [12] OCT Biomarkers in Ocular CLN2 Disease
    Huang, Wei Chieh
    Atiskova, Yevgeniya
    Ohnsman, Christina M.
    Dulz, Simon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [13] Psychometric Validation of the CLN2 Quality of Life Questionnaire in Participants with CLN2 Disease Treated with Cerliponase Alfa
    Due, Christina
    Quinn, Jennifer
    Gissen, Paul
    Schulz, Angela
    Specchio, Nicola
    de los Reyes, Emily
    Butt, Thomas
    HEALTHCARE, 2024, 12 (22)
  • [14] A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes
    Vicki J. Swier
    Katherine A. White
    Tyler B. Johnson
    Jessica C. Sieren
    Hans J. Johnson
    Kevin Knoernschild
    Xiaojun Wang
    Frank A. Rohret
    Christopher S. Rogers
    David A. Pearce
    Jon J. Brudvig
    Jill M. Weimer
    Neurotherapeutics, 2022, 19 : 1905 - 1919
  • [15] Mitochondrial abnormalities in CLN2 and CLN3 forms of Batten disease
    Dawson, G
    Kilkus, J
    Siakotos, AN
    Singh, I
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1996, 29 (2-3) : 227 - 235
  • [16] Revoking the Seize Order: Preventing Spontaneous Seizures With AAV in a CLN2 Mouse Model
    Buchanan, Gordon F.
    EPILEPSY CURRENTS, 2023, 23 (06) : 386 - 388
  • [17] A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes
    Swier, Vicki J.
    White, Katherine A.
    Johnson, Tyler B.
    Sieren, Jessica C.
    Johnson, Hans J.
    Knoernschild, Kevin
    Wang, Xiaojun
    Rohret, Frank A.
    Rogers, Christopher S.
    Pearce, David A.
    Brudvig, Jon J.
    Weimer, Jill M.
    NEUROTHERAPEUTICS, 2022, 19 (06) : 1905 - 1919
  • [18] Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis
    Passini, MA
    Dodge, JC
    Bu, J
    Yang, W
    Zhao, Q
    Sondhi, D
    Hackett, NR
    Kaminsky, SM
    Mao, QW
    Shihabuddin, LS
    Cheng, SH
    Sleat, DE
    Stewart, GR
    Davidson, BL
    Lobel, P
    Crystal, RG
    JOURNAL OF NEUROSCIENCE, 2006, 26 (05): : 1334 - 1342
  • [19] Cerliponase alfa for CLN2 disease, a promising therapy
    Aylward, Shawn C.
    Pindrik, Jonathan
    Abreu, Nicolas J.
    Cherny, W. Bruce
    O'Neal, Matthew
    de Los Reyes, Emily
    EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (11): : 445 - 454
  • [20] LINCE project: A fast diagnosis of CLN2 disease
    Crujeiras, Pablo
    Rodrigues, Daniel C.
    Cocho, Jose
    Couce Pico, Maria Luz
    Colon Mejeras, Cristobal
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S44 - S44